BRPI0414450A - derivados de diazabicicloalcano substituìdos como ligandos nos receptores de alfa 7 acetilcolina nicotìnica - Google Patents

derivados de diazabicicloalcano substituìdos como ligandos nos receptores de alfa 7 acetilcolina nicotìnica

Info

Publication number
BRPI0414450A
BRPI0414450A BRPI0414450-3A BRPI0414450A BRPI0414450A BR PI0414450 A BRPI0414450 A BR PI0414450A BR PI0414450 A BRPI0414450 A BR PI0414450A BR PI0414450 A BRPI0414450 A BR PI0414450A
Authority
BR
Brazil
Prior art keywords
compounds
substituted
ligands
phenyl
nicotinically
Prior art date
Application number
BRPI0414450-3A
Other languages
English (en)
Inventor
Tao Li
Anwer Basha
William H Bunnelle
Michael J Dart
Megan E Gallagher
Jianguo Ji
Jennifer M Pace
Keith B Ryther
Karin R Tietje
Kathleen H Mortell
Diana L Nersesian
Michael R Schrimpf
Original Assignee
Abbott Laboratoires
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratoires filed Critical Abbott Laboratoires
Publication of BRPI0414450A publication Critical patent/BRPI0414450A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"DERIVADOS DE DIAZABICICLOALCANO SUBSTITUìDOS COMO LIGANDOS NOS RECEPTORES DE ALFA 7 ACETILCOLINA NICOTìNICA". Compostos da fórmula (1) Z Ar~ 1~ Ar~ 2~ onde Z é uma amina diazabicíclica, Ar~ 1~ é um anel aromático com 5 ou 6 membros, e Ar~ 2~ é escolhido do grupo consistindo de um anel heteroarila de 5 ou 6 membros, substituído ou insubstituido; um anel heteroarila bicíclico substituído ou insubstituido; 3,4 (metilenodioxi)fenila; carbazolila; tetrahidrocarbazolila; naftila; e fenila; onde a fenila é substituída por 0, 1, 2, ou 3 substituintes nas posições meta ou para . Os compostos são úteis no tratamento de condições ou distúrbios evitados ou melhorados por ligandos <244>7 nAChR. Também são apresentadas composições farmacêuticas compreendendo compostos da fórmula (I), e métodos para o uso de tais compostos e composições.
BRPI0414450-3A 2003-09-19 2004-09-17 derivados de diazabicicloalcano substituìdos como ligandos nos receptores de alfa 7 acetilcolina nicotìnica BRPI0414450A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/666,884 US20050065178A1 (en) 2003-09-19 2003-09-19 Substituted diazabicycloakane derivatives
PCT/US2004/030735 WO2005028477A1 (en) 2003-09-19 2004-09-17 Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acety lcholine receptors

Publications (1)

Publication Number Publication Date
BRPI0414450A true BRPI0414450A (pt) 2006-11-14

Family

ID=34313215

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414450-3A BRPI0414450A (pt) 2003-09-19 2004-09-17 derivados de diazabicicloalcano substituìdos como ligandos nos receptores de alfa 7 acetilcolina nicotìnica

Country Status (13)

Country Link
US (1) US20050065178A1 (pt)
EP (2) EP2316836A1 (pt)
JP (1) JP2007521323A (pt)
KR (1) KR20060109428A (pt)
CN (1) CN101189233A (pt)
AU (2) AU2004274492B2 (pt)
BR (1) BRPI0414450A (pt)
CA (1) CA2538789A1 (pt)
IL (1) IL174400A0 (pt)
NZ (1) NZ545789A (pt)
TW (1) TW200526667A (pt)
WO (1) WO2005028477A1 (pt)
ZA (1) ZA200602274B (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1799667B1 (en) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
EP1804799B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US7767677B2 (en) * 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
AU2005298693A1 (en) * 2004-10-20 2006-05-04 Neurosearch A/S Novel diazabicyclic aryl derivatives and their medical use
EP1863485A2 (en) * 2005-03-18 2007-12-12 Abbott Laboratories Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
US7897766B2 (en) * 2005-09-23 2011-03-01 Abbott Laboratories Amino-aza-adamantane derivatives and methods of use
US7504474B2 (en) * 2005-12-21 2009-03-17 E. I. Du Pont De Nemours And Company Poly(trimethylene therephthalate) continuous manufacturing process
US7524921B2 (en) * 2005-12-21 2009-04-28 E. I. Du Pont De Nemours And Company Continuous manufacture of poly(trimethylene terephthalate)
US7531617B2 (en) * 2005-12-21 2009-05-12 E. I. Du Pont De Nemours And Company Continuous process for producing poly(trimethylene terephthalate)
CA2659762A1 (en) * 2006-06-27 2008-01-03 Abbott Laboratories Thiazoline and oxazoline derivatives and their methods of use
MX2008016338A (es) * 2006-06-27 2009-01-16 Abbott Lab Derivados de pirrol y sus metodos de uso.
EP2049110B1 (en) * 2006-07-14 2014-08-20 Merck Sharp & Dohme Corp. Bridged diazepan orexin receptor antagonists
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
US8076350B2 (en) 2006-12-22 2011-12-13 Abbott Laboratories Spirocyclic azaadamantane derivatives and methods of use
CA2705296A1 (en) * 2007-11-21 2009-05-28 Abbott Laboratories Biaryl substituted azabicyclic alkane derivatives as nicotinic acetylcholine receptor activity modulators
MX2010005650A (es) * 2007-11-21 2010-06-02 Abbott Lab Derivados de diazabicicloalcano substituidos con biarilo.
US20090221648A1 (en) * 2007-12-21 2009-09-03 Abbott Laboratories Compositions for treatment of cognitive disorders
US8383657B2 (en) * 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
US8536221B2 (en) * 2008-02-07 2013-09-17 Abbvie Inc. Amide derivatives as positive allosteric modulators and methods of use thereof
US7786171B2 (en) 2008-04-04 2010-08-31 Abbott Laboratories Amide derivatives as positive allosteric modulators and methods of use thereof
US8148408B2 (en) * 2008-05-09 2012-04-03 Abbott Laboratories Selective substituted pyridine ligands for neuronal nicotinic receptors
FR2937641A1 (fr) 2008-10-28 2010-04-30 Sanofi Aventis Derives d'urees de tropane, leur preparation et leur application en therapeutique
EP2387575B1 (en) 2009-01-15 2013-09-04 Anvyl, LLC Alpha7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof
WO2010145208A1 (en) * 2009-06-19 2010-12-23 Abbott Laboratories Diazahomoadamantane derivatives and methods of use thereof
US8796297B2 (en) * 2009-06-30 2014-08-05 Abbvie Inc. 4-substituted-2-amino-pyrimidine derivatives
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
EP2491031B1 (en) 2009-10-23 2013-08-07 Janssen Pharmaceutica N.V. Fused heterocyclic compounds as orexin receptor modulators
EP2491034B1 (en) 2009-10-23 2013-12-18 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds as orexin receptor modulators
ME03452B (me) 2009-10-23 2020-01-20 Janssen Pharmaceutica Nv Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora
EP2619205B1 (en) 2010-09-23 2017-05-17 AbbVie Bahamas Ltd. Monohydrate of an azaadamantane derivative
US20140171448A1 (en) 2011-01-27 2014-06-19 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
EA201391348A8 (ru) 2011-03-18 2014-11-28 Новартис Аг КОМБИНАЦИИ АКТИВАТОРОВ АЛЬФА-7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И АНТАГОНИСТОВ mGluR5, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ ПРИ ВЫЗВАННОЙ ДОПАМИНОМ ДИСКИНЕЗИИ, СВЯЗАННОЙ С БОЛЕЗНЬЮ ПАРКИНСОНА
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
CN103619354A (zh) 2011-06-30 2014-03-05 东丽株式会社 止痒剂
TW201311698A (zh) * 2011-08-22 2013-03-16 Targacept Inc 作為神經元菸鹼乙醯膽鹼受體配位體之１，４－二氮雜雙環［３．２．２］壬烷
IN2014CN03647A (pt) 2011-10-20 2015-10-09 Novartis Ag
US9359367B2 (en) 2012-07-09 2016-06-07 Lupin Limited Tetrahydroquinazolinone derivatives as PARP inhibitors
CN102977105A (zh) * 2012-11-30 2013-03-20 盛世泰科生物医药技术(苏州)有限公司 3（甲基），7-二氮杂双环辛烷的合成
BR112015013771B1 (pt) 2012-12-11 2022-10-04 Novartis Ag Composição que compreende um ativador do receptor alfa 7, nicotínico de acetilcolina (nachr) como biomarcador preditivo de resposta ao tratamento de ativador do dito receptor
US9040712B2 (en) * 2013-01-23 2015-05-26 Novartis Ag Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
US10301294B2 (en) 2013-03-13 2019-05-28 The Broad Institute Inc. Compounds for the treatment of tuberculosis
KR20230116948A (ko) 2016-03-10 2023-08-04 얀센 파마슈티카 엔.브이. 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법
CN107188900B (zh) * 2017-05-27 2019-09-06 北京师范大学 α7烟碱型乙酰胆碱受体的配体化合物及其应用
JP2021524459A (ja) * 2018-05-24 2021-09-13 バイエル・アクチエンゲゼルシヤフト ハロゲン化ｎ−アリールピラゾールの製造方法
RS65638B1 (sr) 2018-11-14 2024-07-31 Janssen Pharmaceutica Nv Unapređene sintetičke metode pravljenja fuzionisanih heterocikličnih jedinjenja kao modulatora receptora oreksina
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
CN120097862A (zh) 2019-08-07 2025-06-06 詹森药业有限公司 制备作为食欲素受体调节剂的(2h-1,2,3-三唑-2-基)苯基化合物的改进的合成方法
WO2024189472A1 (en) 2023-03-14 2024-09-19 Janssen Pharmaceutica Nv Improved synthetic methods of making substituted pyrimidine intermediates for synthesis of orexin receptor modulators

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59009705D1 (de) 1989-04-17 1995-11-02 Bayer Ag Verfahren zur Herstellung von 2,7-Diazabicyclo(3.3.0)octanen.
US5478939A (en) * 1994-07-20 1995-12-26 American Cyanamid Company (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives
AU717744B2 (en) * 1996-01-15 2000-03-30 Janssen Pharmaceutica N.V. Angiogenesis inhibiting pyridazinamines
JP2000026408A (ja) 1998-07-02 2000-01-25 Dai Ichi Seiyaku Co Ltd 対掌体的に純粋なピロリジン誘導体、その塩、それらの製造方法
FR2786769B1 (fr) * 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
EP1147112B1 (en) * 1999-01-29 2003-10-29 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
US7265115B2 (en) * 1999-01-29 2007-09-04 Abbott Laboratories Diazabicyclic CNS active agents
MXPA02005884A (es) * 1999-12-14 2002-10-23 Neurosearch As Heteroaril-diazabicicloalcanos novedosos.
MY145722A (en) * 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents
EP1289996B1 (en) * 2000-05-25 2005-04-06 Targacept, Inc. Heteroaryldiazabicycloalkanes as nicotinic cholinergic receptor ligands
EP1322633A2 (en) 2000-05-31 2003-07-02 Aventis Pharma Deutschland GmbH Aryloxy ester and acid compounds
ATE287888T1 (de) * 2000-07-04 2005-02-15 Neurosearch As Aryl- und heteroaryldiazabicycloalkane, deren zubereitung und verwendung
DE60229114D1 (en) * 2001-03-02 2008-11-13 Axys Pharm Inc Cathepsincystein-proteasehemmer
ATE289310T1 (de) * 2001-06-01 2005-03-15 Neurosearch As Heteroaryl-diazabicycloalkanderivaten als cns- modulatoren
MXPA04010966A (es) * 2002-05-07 2005-01-25 Neurosearch As Derivados novedosos de biarilo diazabiciclico.
DE10232572A1 (de) * 2002-07-18 2004-02-05 Bayer Ag Neue 2,5-disubstituierte Pyrimidinderivate

Also Published As

Publication number Publication date
NZ545789A (en) 2010-03-26
JP2007521323A (ja) 2007-08-02
IL174400A0 (en) 2006-08-01
AU2004274492A1 (en) 2005-03-31
WO2005028477A1 (en) 2005-03-31
AU2010202299A1 (en) 2010-06-24
US20050065178A1 (en) 2005-03-24
TW200526667A (en) 2005-08-16
ZA200602274B (en) 2007-11-28
CA2538789A1 (en) 2005-03-31
EP1664045A1 (en) 2006-06-07
EP2316836A1 (en) 2011-05-04
AU2004274492B2 (en) 2010-04-29
KR20060109428A (ko) 2006-10-20
CN101189233A (zh) 2008-05-28

Similar Documents

Publication Publication Date Title
BRPI0612141A2 (pt) derivados de quinuclidina substituìdos com biciclo-heterociclos fundidos
BRPI0417948A (pt) derivados de quinuclidina substituìda por bicicloheterociclo fundido
BR122017028096B8 (pt) composto, composição farmacêutica, e, uso do composto
BR0208907A (pt) Composto uso de um composto, composição farmacêutica, métodos para a terapia da dor em um animal de sangue quente e para a redução seletiva de uma porção nitro orto para um substituinte amino em um anel fenila ou piridila de um composto.
BR0010391A (pt) Composto, composição farmacêutica, método de preparação de um composto, e, uso de um composto
BRPI0407976A (pt) tetrahidroisoquinolinas substituìdas em 2,5 e 2,6 para uso como moduladores de 5-ht6
BRPI0517461A (pt) compostos farmacêuticos
BR0016396A (pt) Novos antagonistas do receptor p2x7 para uso no tratamento de doenças inflamatórias, imunes ou cardiovasculares
BRPI0409241A (pt) compostos bicìclicos como antagonistas do receptor de nr2b, composições farmacêuticas compreendendo os mesmos e seu uso
BRPI0413232B8 (pt) composto tendo atividade inibitória contra transportador dependente de sódio, composição farmacêutica compreendendo o composto, uso do composto na preparação de um medicamento e processo para a preparação do composto
ATE377597T1 (de) Anilinochinazoline als protein-tyrosin- kinasehemmer
BR0014352A (pt) Cetoenóis espirocìclicos substituìdos por trifluormetila
BR0306208A (pt) Compostos de dibenzilamina e seu uso farmacêutico
BR0312560A (pt) Novas espiropiperidinas ou espiropirrolidinas tricìclicas
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
BR9914370A (pt) Derivados de tetraidrobenzazepina úteis comomoduladores de receptores para a dopamina d3(agentes antipsicóticos)
EA199800882A1 (ru) Производные замешенных индазолов, их применение в качестве ингибиторов фосфодиэстеразы (фдэ) iv и получение фактора некроза опухолей (фно)
BR0311541A (pt) indol, azaindol e 4-aquenil piperidina amidas heterocìclicas relacionadas
BRPI0413094A (pt) derivados de quinolina e seu uso em terapia
UY26048A1 (es) Derivados de piridopiranoacepinas, su preparacion y su aplicacion terapeutica
BRPI0418255A (pt) derivados de piperazina e piperidina n-substituìdos
NO20063355L (no) Nye trisykliske spiroderivater som modulatorer for kemokinreseptoraktivitet
BRPI0315958B8 (pt) composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto
BRPI0615248A2 (pt) derivado tendo atividade agonista de ppar
DK1194415T3 (da) Nye piperazinylalkylthiopyrimidinderivater, farmaceutiske sammensætninger indeholdende disse samt en fremgangsmåde til deres fremstilling

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2167 DE 17/07/2012.